Latest Press Releases

BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research
Press Release Nov 11, 2026
BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research

Zero-login digital companion offers immediate breathing resets and vetted trauma support today, while Xycota prepares preclinical BDNF/TrkB psilocybin research for practical outpatient care.

  • Free, Off-Record PTSD Support Available Today: Live at https://xycota.com/ptsd, the free hub requires no account or cloud data storage and offers guided 60-second physiological sigh, box breathing, and 5-4-3-2-1 sensory grounding tools, a private browser-only log, and a confidential support matcher for veterans, first responders, and families.
  • Sub-Perceptual, At-Home Psilocybin Research (XYCO-02): Alongside free community tools, Xycota is preparing a Canadian clinical trial application with KGK Science to test whether low-dose oral psilocybin can engage the brain's BDNF/TrkB repair pathway at home without a six-to-eight-hour clinic trip.
  • Two-Company Structure and Shareholder Safeguards: BioAdaptives, Inc.'s (OTCID:BDPT) definitive agreement to acquire Xycota keeps biotech and nutraceutical operations separate, includes conditional funding for a proposed nutraceutical spin-off, and enforces a 12-month founder lock-up and daily note resale limits.